Davare Lab

[Davare Lab @DavareLab]

@Moranaaa @RutgersCancer @RWJBarnabas @Moranaaa @ChrisFebres Fantastic collaboration, Thank you!
Our paper gets to the crux of the formidable clinical challenge posted by #GBM and yet second line targeted options should not be discounted.

[Morana Vojnic, MD, MBA @Moranaaa]

It is with great honor that I share our most recent publication, exploring actionability of acquired #PDGFRA fusions in #GBM. We show evidence of clonal sweep after exposure to an #EGFR monoclonal antibody and successful targeting of the newly acquired MDM2-PDGFRA fusion. This emphasizes the importance of repeat #NGS in patients with recurrent #GBM, evolution of #glioblastoma through several rounds of therapy and proactive monitoring and treatment through its evolution. Thank you to all my collaborators! @DavareLab @ChrisFebres @RandyDAmico_MD @johnboockvar @tamikawong1163 @JLG_Marti @SaeedAsiry @NaturePortfolio @Nature_NPJ @NeuroOnc https://t.co/HfbI70HFOr

[Davare Lab @DavareLab]

@TejasPatilMD @lcsmchat @OncoAlert Thanks, Tejas!

[Davare Lab @DavareLab]

@MLadanyi Thank you, Marc!

[Davare Lab @DavareLab]

Most negative results remain unpublished, creating blind spots in AI training and risking suggestions of already-failed ideas. AI can transform science—but only if it sees the full record of scientific successes and failures. https://t.co/Adop48xuRT
#AI #OpenScience #scicomm

[Davare Lab @DavareLab]

@RobertKennedyJr @RobertKennedyJr Happy to see your support! Hope NIH will continue to support rigorous basic and translational research for rare cancers, including childhood cancers.

[Davare Lab @DavareLab]

@VPrasadMDMPH You make some good points. Reproducibility is a serious issue in our field. So garbage in, garbage out is a liability of this approach. We need to invest more in rigorous basic science research to generate quality datasets for AI training to maximize potential.

[Davare Lab @DavareLab]

@wgibson @DrSarcoma @DavareLab thrilled to partner with the group for tackling this rare cancer!

[OHSU Knight Cancer Institute @OHSUKnight]

“When I met Dr. Cetnar, he had an associate who was doing research with ROS1.

They told me my diagnosis, explained everything about it, and gave me so much relief and hope I said, ‘Can I hug both of you? You both gave me my life back.’"

Clare's story: https://t.co/dIoPu5zy8b

[Davare Lab @DavareLab]

@TejasPatilMD @ros1cancer Thanks, Tejas!

[Davare Lab @DavareLab]

Loss of ROS1's extracellular domain may suffice for catalytic activation. However, the 5' fusion partner's promoter/enhancer will be required to drive its expression in diverse cancer cell lineages, as ROS1 expression is normally highly restricted in most adult human tissues.

[Davare Lab @DavareLab]

ROS1 researchers & enthusiasts! Check our new paper: loss of ROS1's extracellular domain alone drives oncogenic activity, no N-terminal fusion partner needed. Dreaming of future cryo-EM studies... funding willing!
https://t.co/jEzskKlDcq

[Davare Lab @DavareLab]

@OHSUKnight @KuniFoundation Gratitude for the Kuni Foundation for recognizing this gap! We are excited to partner with up @OHSUOrtho @OHSUKnight @OHSUDoernbecher colleagues on this meaningful project.
@PapeOhsu

[OHSU Knight Cancer Institute @OHSUKnight]

“This effort fills a critical gap in pediatric oncology and will accelerate effective treatments for youth impacted by these devastating bone cancers.”

- @KuniFoundation president Angela Hult: https://t.co/xP5Gyh6XFq

[Rajat Thawani @rajatthawani]

Read out manuscript "TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers" in @Nature_NPJ
This collaborative work from @DavareLab @alexdrilon shows data on the use of type II TKIs in ROS1 fusion cancers with L2086F mutation

https://t.co/qNN3OF3awX

[Davare Lab @DavareLab]

@MLadanyi 👏

[Barak Rotblat @BarakRotblat]

PDX vs. original tumor in childhood cancer👇

[Davare Lab @DavareLab]

@juliamaxson Unruly felines who love typing 777rrhs13ty etc. in the middle of important drafts! 😀